Omicron: A SARS-CoV-2 variant of real concern

Pia Gattinger; Inna Tulaeva; Kristina Borochova; Bernhard Kratzer; Doris Trapin; Anna Kropfmüller; Winfried F Pickl; Rudolf Valenta

doi:10.1111/all.15264

Omicron: A SARS-CoV-2 variant of real concern

Pia Gattinger, Inna Tulaeva, Kristina Borochova, Bernhard Kratzer, Doris Trapin, Anna Kropfmüller, Winfried F Pickl, Rudolf Valenta

Scientific Working Group Allergology and Immunology

Research output: Journal article (peer-reviewed) › Letter/short communication

11 Citations (Scopus)

Original language	English
Pages (from-to)	1616-1620
Number of pages	5
Journal	Allergy: European Journal of Allergy and Clinical Immunology
Volume	77
Issue number	5
DOIs	https://doi.org/10.1111/all.15264
Publication status	Published - May 2022

Keywords

COVID-19
Humans
Mutation
SARS-CoV-2
Spike Glycoprotein, Coronavirus

Access to Document

10.1111/all.15264

Cite this

@article{4a8c5db13a9046af92214cd27b7542af,

title = "Omicron: A SARS-CoV-2 variant of real concern",

keywords = "COVID-19, Humans, Mutation, SARS-CoV-2, Spike Glycoprotein, Coronavirus",

author = "Pia Gattinger and Inna Tulaeva and Kristina Borochova and Bernhard Kratzer and Doris Trapin and Anna Kropfm{\"u}ller and Pickl, {Winfried F} and Rudolf Valenta",

note = "Funding Information: This study was supported by grants from {\"O}sterreichische Forschungsf{\"o}rderungsgesellschaft, Grant number: 35721032; Austrian Science Fund, Grant number: DK-W1248; Viravaxx AG; Medizinisch-Wissenschaftlichen Fonds des B{\"u}rgermeisters der Bundeshauptstadt Wien, Grant numbers: COVID001 and COVID006. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We wish to acknowledge the help of Doris Werjant-Locmele and Anna Guentcheva regarding the recruitment and administration of study subjects. We are grateful to all individuals who participated in our study. Funding Information: This study was supported by grants from {\"O}sterreichische Forschungsf{\"o}rderungsgesellschaft, Grant number: 35721032; Austrian Science Fund, Grant number: DK‐W1248; Viravaxx AG; Medizinisch‐Wissenschaftlichen Fonds des B{\"u}rgermeisters der Bundeshauptstadt Wien, Grant numbers: COVID001 and COVID006. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Funding Information: Rudolf Valenta has received research grants from HVD Life‐Sciences, Vienna, Austria, WORG Pharmaceuticals, Hangzhou, China and from Viravaxx AG, Vienna, Austria. He serves as consultant for Viravaxx AG and WORG Pharmaceuticals. The other authors have no conflict of interest to declare. ",

year = "2022",

month = may,

doi = "10.1111/all.15264",

language = "English",

volume = "77",

pages = "1616--1620",

journal = "Allergy: European Journal of Allergy and Clinical Immunology",

issn = "0105-4538",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "5",

}

TY - JOUR

T1 - Omicron

T2 - A SARS-CoV-2 variant of real concern

AU - Gattinger, Pia

AU - Tulaeva, Inna

AU - Borochova, Kristina

AU - Kratzer, Bernhard

AU - Trapin, Doris

AU - Kropfmüller, Anna

AU - Pickl, Winfried F

AU - Valenta, Rudolf

N1 - Funding Information: This study was supported by grants from Österreichische Forschungsförderungsgesellschaft, Grant number: 35721032; Austrian Science Fund, Grant number: DK-W1248; Viravaxx AG; Medizinisch-Wissenschaftlichen Fonds des Bürgermeisters der Bundeshauptstadt Wien, Grant numbers: COVID001 and COVID006. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We wish to acknowledge the help of Doris Werjant-Locmele and Anna Guentcheva regarding the recruitment and administration of study subjects. We are grateful to all individuals who participated in our study. Funding Information: This study was supported by grants from Österreichische Forschungsförderungsgesellschaft, Grant number: 35721032; Austrian Science Fund, Grant number: DK‐W1248; Viravaxx AG; Medizinisch‐Wissenschaftlichen Fonds des Bürgermeisters der Bundeshauptstadt Wien, Grant numbers: COVID001 and COVID006. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Funding Information: Rudolf Valenta has received research grants from HVD Life‐Sciences, Vienna, Austria, WORG Pharmaceuticals, Hangzhou, China and from Viravaxx AG, Vienna, Austria. He serves as consultant for Viravaxx AG and WORG Pharmaceuticals. The other authors have no conflict of interest to declare.

PY - 2022/5

Y1 - 2022/5

KW - COVID-19

KW - Humans

KW - Mutation

KW - SARS-CoV-2

KW - Spike Glycoprotein, Coronavirus

UR - http://www.scopus.com/inward/record.url?scp=85125399950&partnerID=8YFLogxK

U2 - 10.1111/all.15264

DO - 10.1111/all.15264

M3 - Letter/short communication

C2 - 35188670

SN - 0105-4538

VL - 77

SP - 1616

EP - 1620

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

IS - 5

ER -

Omicron: A SARS-CoV-2 variant of real concern

Keywords

Access to Document

Other files and links

Cite this